Ligand Pharmaceuticals (LGND) Deferred Taxes (2011 - 2026)

Ligand Pharmaceuticals (LGND) has 16 years of Deferred Taxes data on file, last reported at $13.5 million in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 53.01% year-over-year to $13.5 million; the trailing twelve-month figure through Mar 2026 stood at -$18.0 million (down 140.72% YoY), and the FY2025 full-year result was -$22.7 million, down 243.57% from the prior year.
• Deferred Taxes improved to $13.5 million in Q1 2026, from -$10.6 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $20.7 million in Q2 2024 to a low of -$46.3 million in Q4 2022.
• A 5-year average of -$1.5 million and a median of $325000.0 in 2025 frame the typical range for Deferred Taxes.
• Peak annual rise in Deferred Taxes reached 922.71% in 2022, while the deepest fall reached 12000.51% in 2022.
• Tracing LGND's Deferred Taxes over 5 years: stood at -$46.3 million in 2022, then jumped by 89.34% to -$4.9 million in 2023, then surged by 357.18% to $12.7 million in 2024, then slumped by 183.29% to -$10.6 million in 2025, then surged by 228.01% to $13.5 million in 2026.
• Business Quant data shows LGND's Deferred Taxes at $13.5 million in Q1 2026, -$10.6 million in Q4 2025, and -$21.3 million in Q3 2025.